Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12584827 | 1.00 | CA12 (0.34) | CA12CA14DPP4 | |
| SCHEMBL20793253 | 0.80 | TP53 (0.32) | — | |
| SCHEMBL13233700 | 0.80 | TP53 (0.32) | — | |
| SCHEMBL20793251 | 0.80 | TP53 (0.32) | — | |
| SCHEMBL12837975 | 0.80 | TP53 (0.32) | — | |
| SCHEMBL13534035 | 0.79 | SLC7A5 (0.44) | CA12CA14DPP4 | |
| SCHEMBL22969051 | 0.78 | — | — | |
| SCHEMBL716843 | 0.77 | SMN1; SMN2 (0.41) | — | |
| SCHEMBL43660 | 0.77 | — | — | |
| SCHEMBL8171264 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230038124-A1 | NOVEL SUBSTITUTED CONDENSED RING COMPOUND | Sumitomo Pharma Co., Ltd. (JP) | 2023-02-09 | — | — | US | disclosed |
| US-11510994-B2 | Linkers for improving the stability of bioconjugates and the selectivity of payload release | EqIP, LLC (US) | 2022-11-29 | — | — | US | disclosed |
| US-11066425-B1 | Oxo-substituted compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-07-20 | — | — | US | disclosed |
| EP-2928484-B1 | COMPOUNDS USEFUL IN THE TREATMENT AND/OR CARE OF THE SKIN, HAIR AND/OR MUCOUS MEMBRANES AND THEIR COSMETIC OR PHARMACEUTICAL COMPOSITIONS | LUBRIZOL ADVANCED MAT INC (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20210040127-A1 | ARGINASE INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2021-02-11 | — | — | US | disclosed |
| US-20200407339-A1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF | TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE | 2020-12-31 | — | — | US | disclosed |
| WO-2017192512-A2 | AMPHIPHILIC NANOPARTICLES FOR DELIVERY OF CRISPR BASED THERAPY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-11-09 | — | — | WO | disclosed |
| US-20170267718-A1 | TRIPEPTIDE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | NORTHWEST UNIVERSITY (CN) | 2017-09-21 | — | — | US | disclosed |
| EP-2861581-B9 | 1,2,3,4-Tetrahydroisoquinoline-pyrrolidine derivatives as antagonists of apoptosis (IAPs) for the treatment of cancer. | BRISTOL MYERS SQUIBB CO (US) | 2017-08-30 | — | — | EP | disclosed |
| US-RE44186-E1 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-30 | — | — | US | disclosed |
| WO-2013059278-A2 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2012021704-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2011127350-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011081918-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC (US) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011031904-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011031934-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2010148006-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010099527-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010096462-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC (US) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010091413-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11510994-B2 | Linkers for improving the stability of bioconjugates and the selectivity of payload release | CTSA, CTSS, CTSV | CA12 776/4885CA14 499/4885DPP4 622/4885 |
| US-11066425-B1 | Oxo-substituted compound | CYP51A1, OXA1L, O60361 | CA12 3056/4885CA14 3053/4885DPP4 999/4885 |
| US-20210040127-A1 | ARGINASE INHIBITORS AND METHODS OF USE | ARG1, ARG2, PRMT1 | CA12 918/4885CA14 952/4885DPP4 1492/4885 |
| US-20230038124-A1 | NOVEL SUBSTITUTED CONDENSED RING COMPOUND | CYP51A1, HDAC11, MMP9 | CA12 1232/4885CA14 1594/4885DPP4 590/4885 |
| US-20200407339-A1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF | PTGER1, LOXL1, COL1A1 | CA12 4548/4885CA14 4526/4885DPP4 2516/4885 |
| US-20170267718-A1 | TRIPEPTIDE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | VIP, PREP, ACE | CA12 2010/4885CA14 1031/4885DPP4 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.